Arrow Therapeutics HCV Compound Enters Phase I

28-Nov-2006

Arrow Therapeutics, a London based antiviral drug discovery and development company, has announced that it has initiated a Phase I study of A-831, a small molecule antiviral inhibitor of hepatitis C infection. The study shall evaluate the safety, tolerability and pharmacokinetics of single escalating doses of A-831 in healthy volunteers in the UK.

A-831 targets the NS5a protein and is, according to the company, the first NS5a inhibitor to enter the clinic. A-831 is the first compound from Arrow's approach to the NS5a target. A further Arrow compound, also targeting the NS5a protein but of a completely different chemical structure, is expected to enter preclinical development shortly.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...